JP2020059759A5 - - Google Patents

Download PDF

Info

Publication number
JP2020059759A5
JP2020059759A5 JP2020000332A JP2020000332A JP2020059759A5 JP 2020059759 A5 JP2020059759 A5 JP 2020059759A5 JP 2020000332 A JP2020000332 A JP 2020000332A JP 2020000332 A JP2020000332 A JP 2020000332A JP 2020059759 A5 JP2020059759 A5 JP 2020059759A5
Authority
JP
Japan
Prior art keywords
crystal
morpholinophenylamino
cyanomethyl
pyrimidin
benzamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020000332A
Other languages
English (en)
Japanese (ja)
Other versions
JP6840909B2 (ja
JP2020059759A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2020059759A publication Critical patent/JP2020059759A/ja
Publication of JP2020059759A5 publication Critical patent/JP2020059759A5/ja
Application granted granted Critical
Publication of JP6840909B2 publication Critical patent/JP6840909B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020000332A 2014-06-12 2020-01-06 Ｎ−（シアノメチル）−４−（２−（４−モルホリノフェニルアミノ）ピリミジン−４−イル）ベンズアミド塩酸塩 Active JP6840909B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462011315P 2014-06-12 2014-06-12
US62/011,315 2014-06-12

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018164680A Division JP6883560B2 (ja) 2014-06-12 2018-09-03 Ｎ−（シアノメチル）−４−（２−（４−モルホリノフェニルアミノ）ピリミジン−４−イル）ベンズアミド塩酸塩

Publications (3)

Publication Number Publication Date
JP2020059759A JP2020059759A (ja) 2020-04-16
JP2020059759A5 true JP2020059759A5 (https=) 2020-12-24
JP6840909B2 JP6840909B2 (ja) 2021-03-10

Family

ID=53674249

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2016572271A Active JP6600649B2 (ja) 2014-06-12 2015-06-11 Ｎ−（シアノメチル）−４−（２−（４−モルホリノフェニルアミノ）ピリミジン−４−イル）ベンズアミド塩酸塩
JP2018164680A Active JP6883560B2 (ja) 2014-06-12 2018-09-03 Ｎ−（シアノメチル）−４−（２−（４−モルホリノフェニルアミノ）ピリミジン−４−イル）ベンズアミド塩酸塩
JP2020000332A Active JP6840909B2 (ja) 2014-06-12 2020-01-06 Ｎ−（シアノメチル）−４−（２−（４−モルホリノフェニルアミノ）ピリミジン−４−イル）ベンズアミド塩酸塩
JP2021079700A Active JP7198867B2 (ja) 2014-06-12 2021-05-10 Ｎ－（シアノメチル）－４－（２－（４－モルホリノフェニルアミノ）ピリミジン－４－イル）ベンズアミド塩酸塩
JP2022202374A Active JP7550205B2 (ja) 2014-06-12 2022-12-19 Ｎ－（シアノメチル）－４－（２－（４－モルホリノフェニルアミノ）ピリミジン－４－イル）ベンズアミド塩酸塩

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2016572271A Active JP6600649B2 (ja) 2014-06-12 2015-06-11 Ｎ−（シアノメチル）−４−（２−（４−モルホリノフェニルアミノ）ピリミジン−４−イル）ベンズアミド塩酸塩
JP2018164680A Active JP6883560B2 (ja) 2014-06-12 2018-09-03 Ｎ−（シアノメチル）−４−（２−（４−モルホリノフェニルアミノ）ピリミジン−４−イル）ベンズアミド塩酸塩

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021079700A Active JP7198867B2 (ja) 2014-06-12 2021-05-10 Ｎ－（シアノメチル）－４－（２－（４－モルホリノフェニルアミノ）ピリミジン－４－イル）ベンズアミド塩酸塩
JP2022202374A Active JP7550205B2 (ja) 2014-06-12 2022-12-19 Ｎ－（シアノメチル）－４－（２－（４－モルホリノフェニルアミノ）ピリミジン－４－イル）ベンズアミド塩酸塩

Country Status (36)

Country Link
US (5) US9469613B2 (https=)
EP (3) EP3154950B1 (https=)
JP (5) JP6600649B2 (https=)
KR (1) KR101928225B1 (https=)
CN (2) CN106458929A (https=)
AP (1) AP2016009551A0 (https=)
AR (1) AR100818A1 (https=)
AU (1) AU2015274554B9 (https=)
BR (1) BR112016028749A2 (https=)
CA (1) CA2951883C (https=)
CR (1) CR20160575A (https=)
CU (1) CU20160183A7 (https=)
CY (2) CY1123604T1 (https=)
DK (1) DK3154950T3 (https=)
EA (1) EA032639B1 (https=)
EC (1) ECSP16093323A (https=)
ES (1) ES2822773T3 (https=)
FI (1) FIC20240025I1 (https=)
FR (1) FR24C1030I2 (https=)
HR (1) HRP20201492T1 (https=)
HU (2) HUE051360T2 (https=)
IL (3) IL249038B (https=)
LT (2) LT3154950T (https=)
MA (1) MA40067A (https=)
MX (3) MX374541B (https=)
NL (1) NL301282I2 (https=)
NZ (1) NZ725966A (https=)
PH (1) PH12016502461A1 (https=)
PL (1) PL3154950T3 (https=)
PT (1) PT3154950T (https=)
RS (1) RS61065B1 (https=)
SG (2) SG11201610079VA (https=)
SI (1) SI3154950T1 (https=)
TW (3) TWI729644B (https=)
UY (1) UY36166A (https=)
WO (1) WO2015191846A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI729644B (zh) * 2014-06-12 2021-06-01 美商西爾拉癌症醫學公司 N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺
CN106316963B (zh) * 2015-06-26 2021-06-08 苏州泽璟生物制药股份有限公司 吗啡啉苯基氨基嘧啶化合物或其盐的多晶型物
CN106316964B (zh) * 2015-06-26 2019-06-25 苏州泽璟生物制药股份有限公司 苯基氨基嘧啶化合物或其盐的多晶型物
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
WO2018031579A1 (en) 2016-08-10 2018-02-15 Gilead Sciences, Inc. Momelotinib for treating of acvr1 -mediated diseases
KR102942294B1 (ko) * 2018-05-15 2026-03-23 장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 소분자 이지에프알 억제제를 포함하는 약학 조성물 및 그의 제조 방법
KR20210047308A (ko) 2018-08-21 2021-04-29 시에라 온코로지, 인코퍼레이티드 골수섬유증을 치료하는 혈소판 수-불특정 방법
EP3923948A4 (en) * 2019-02-12 2022-11-16 Impact Biomedicines, Inc. CRYSTALLINE SHAPES OF A JAK2 INHIBITOR
CN114761013A (zh) 2019-09-27 2022-07-15 迪斯克医药公司 治疗骨髓纤维化和相关病症的方法
WO2021231798A1 (en) 2020-05-13 2021-11-18 Disc Medicine, Inc. Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
CN117794545A (zh) 2021-07-30 2024-03-29 葛兰素史密斯克莱有限责任公司 骨髓纤维化的治疗中的生物标志物和患者选择
EP4384181A2 (en) 2021-08-10 2024-06-19 GlaxoSmithKline LLC Momelotinib combination therapy
WO2023023473A1 (en) 2021-08-16 2023-02-23 Sierra Oncology, Inc. Methods of using momelotinib to treat chronic kidney disease
CN115957221B (zh) * 2021-10-09 2026-01-06 广东东阳光药业股份有限公司 抗纤维化组合物
WO2023152773A1 (en) * 2022-02-14 2023-08-17 Dr. Reddy's Institute Of Life Sciences Solid forms of momelotinib salts and improved processes for the preparation of momelotinib
CN119704552B (zh) * 2025-02-08 2025-06-13 泰州南洋塑料制品有限公司 一种电池槽注塑模具及边缘毛刺废料处理回收装置

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3481932A (en) 1967-09-01 1969-12-02 Searle & Co 2-anilino-5-methyl-6-phenylpyrimidines and congeners
US4943593A (en) 1988-02-25 1990-07-24 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5182297A (en) 1988-02-25 1993-01-26 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5021456A (en) 1988-02-25 1991-06-04 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4965288A (en) 1988-02-25 1990-10-23 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5059714A (en) 1988-02-25 1991-10-22 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5252608A (en) 1988-02-25 1993-10-12 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5120764A (en) 1988-11-01 1992-06-09 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4997854A (en) 1989-08-25 1991-03-05 Trustees Of Boston University Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamine analogue substrates
US5559714A (en) 1990-10-22 1996-09-24 Hallmark Cards, Incorporated Method and apparatus for display sequencing personalized social occasion products
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
US6376531B1 (en) * 1998-11-13 2002-04-23 Rupert Charles Bell Method of treatment using deuterium compounds
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
GB9924862D0 (en) 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
US7122544B2 (en) 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
US20040102455A1 (en) 2001-01-30 2004-05-27 Burns Christopher John Method of inhibiting kinases
EP1373257B9 (en) 2001-03-29 2008-10-15 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
FR2828206B1 (fr) 2001-08-03 2004-09-24 Centre Nat Rech Scient Utilisation d'inhibiteurs des lysyl oxydases pour la culture cellulaire et le genie tissulaire
US6433018B1 (en) 2001-08-31 2002-08-13 The Research Foundation Of State University Of New York Method for reducing hypertrophy and ischemia
RU2295329C2 (ru) 2001-09-12 2007-03-20 ВиРекс Медикал Корпорейшн Перекрывающее кровоток твердофазное средство с покрытием из иммобилизованного связывающего средства
DE60317198T2 (de) 2002-05-23 2008-12-04 Cytopia Research Pty. Ltd., Richmond Proteinkinaseinhibitoren
MXPA05001804A (es) 2002-08-14 2005-05-27 Vertex Pharma Inhibidores de proteinas cinasas y usos de los mismos.
JP2006512314A (ja) 2002-11-01 2006-04-13 バーテックス ファーマシューティカルズ インコーポレイテッド Ｊａｋインヒビターおよび他のプロテインキナーゼインヒビターとしての組成物の使用
EP1562938B1 (en) 2002-11-04 2007-08-29 Vertex Pharmaceuticals Incorporated Heteroaryl-pyrimidine derivatives as jak inhibitors
EP1560824A1 (en) 2002-11-05 2005-08-10 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of jak and other protein kinases
GB0317841D0 (en) 2003-07-30 2003-09-03 Cyclacel Ltd Compound
EP1648875A1 (en) 2003-07-30 2006-04-26 Cyclacel Limited 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
SI2612862T1 (sl) 2004-05-13 2017-04-26 Icos Corporation Kinazolini kot inhibitorji humane fosfatidilinozitol 3-kinaze delta
MX2007004488A (es) 2004-10-13 2007-09-11 Wyeth Corp Analogos de anilino-pirimidina n-bencenosulfonilo sustituidos.
US7593820B2 (en) 2005-05-12 2009-09-22 Cytopia Research Pty Ltd Crystal structure of human Janus Kinase 2 (JAK2) and uses thereof
KR20080110998A (ko) 2006-01-30 2008-12-22 엑셀리시스, 인코포레이티드 Ｊａｋ­２ 조절자로서 ４­아릴­２­아미노­피리미딘 또는 4­아릴­２­아미노알킬­피리미딘 및 이들을 포함하는 약제학적 조성물
BRPI0708347A2 (pt) 2006-02-28 2011-05-24 Cytopia Res Pty Ltd inibição jak2 como um tratamento da hipertensão arterial pulmonar
FR2911139A1 (fr) 2007-01-05 2008-07-11 Sanofi Aventis Sa Nouveaux derives de phenyl-(4-phenyl-pyrimidin-2-yl)amines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
AU2016200866B2 (en) 2007-03-12 2017-06-22 Glaxosmithkline Llc Phenyl amino pyrimidine compounds and uses thereof
HRP20151386T1 (hr) 2007-03-12 2016-02-26 Ym Biosciences Australia Pty Ltd Fenil aminopirimidinski spojevi i njihova primjena
AU2013201306B2 (en) 2007-03-12 2015-11-12 Glaxosmithkline Llc Phenyl Amino Pyrimidine Compounds and Uses Thereof
US8530480B2 (en) 2007-09-04 2013-09-10 The Scripps Research Institute Substituted pyrimidinyl-amines as protein kinase inhibitors
WO2009029998A1 (en) 2007-09-06 2009-03-12 Cytopia Research Pty Ltd Retrometabolic compounds
WO2009073575A2 (en) 2007-11-30 2009-06-11 Oregon Health & Science University Methods for treating induced cellular proliferative disorders
MX2011001426A (es) 2008-08-05 2011-03-21 Targegen Inc Metodos para tratar la talasemia.
UA102128C2 (en) 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate
US8450321B2 (en) 2008-12-08 2013-05-28 Gilead Connecticut, Inc. 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
WO2010141946A1 (en) 2009-06-05 2010-12-09 Cell Targeting, Inc. Peptide-coated cell localization to diseased or damaged tissues and methods related thereto
JP5086385B2 (ja) * 2010-03-08 2012-11-28 日立オートモティブシステムズ株式会社 電動パワーステアリング制御装置
BR112012030711B1 (pt) 2010-05-31 2020-10-13 Ono Pharmaceutical Co. Ltd derivado de purinona
WO2012071612A1 (en) * 2010-12-03 2012-06-07 Ym Biosciences Australia Pty Ltd Treatment of jak2-mediated conditions
MD20130089A2 (ro) 2011-05-02 2014-05-31 Ym Biosciences Australia Pty Ltd Metodă de tratament al mielomului multiplu
US8809359B2 (en) 2012-06-29 2014-08-19 Ym Biosciences Australia Pty Ltd Phenyl amino pyrimidine bicyclic compounds and uses thereof
JPWO2014051056A1 (ja) * 2012-09-28 2016-08-22 東レ株式会社 グリシン誘導体の結晶及びその医薬用途
JP2016505015A (ja) 2013-01-09 2016-02-18 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化モメロチニブ（ｍｏｍｅｌｏｔｉｎｉｂ）
CN103965114B (zh) 2013-01-28 2016-01-06 苏州泽璟生物制药有限公司 氘代的苯基氨基嘧啶化合物以及包含该化合物的药物组合物
TWI729644B (zh) * 2014-06-12 2021-06-01 美商西爾拉癌症醫學公司 N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺
CN106316964B (zh) * 2015-06-26 2019-06-25 苏州泽璟生物制药股份有限公司 苯基氨基嘧啶化合物或其盐的多晶型物

Similar Documents

Publication Publication Date Title
JP2020059759A5 (https=)
IL276948A (en) N- (Cyanomethyl) -4– (2– (4-morpholinophenylamino) pyrimidine-4-il) salts Benzamide hydrochloride
JP4628974B2 (ja) イバブラジン塩酸塩のγ−結晶形態、その製造方法およびそれを含む医薬組成物
JP2014074067A (ja) メシル酸イマチニブのｆ、ｇ、ｈ、ｉおよびｋ結晶形
JP6008937B2 (ja) １−（３−シアノ−１−イソプロピル−インドール−５−イル）ピラゾール−４−カルボン酸の結晶形とその製造方法
EP1713792B1 (en) SALT OF 4-(4-METHYLPIPERAZIN-1-YLMETHYL)-n- 4-METHYL-3 -(4-PYRIDIN-3-YL)PYRIMIDIN-2-YLAMINO)PHENYL-BENZAMIDE MALONATE
JP6830888B2 (ja) Ｊａｋ阻害剤の硫酸水素塩の結晶形およびその製造方法
JP2009506014A5 (https=)
CN101243066A (zh) 甲磺酸伊马替尼的δ和ε晶形
AU2021400317A1 (en) Solid forms of a compound
ES2814499T3 (es) Formas en estado sólido de sales de Nilotinib
JP2009517353A5 (https=)
JP2012512145A (ja) フリバンセリンの結晶性の塩形態
JP2024045113A5 (https=)
MX2013010702A (es) Nueva forma cristalina vii de la agomelatina, sus metodos de preparacion, aplicaciones y composiciones farmaceuticas que la contienen.
MX2013010634A (es) Cristal mixto de agomelatina (forma-viii), sus metodos de preparacion y aplicaciones y composiciones farmaceuticas que le contienen.
WO2011064216A1 (en) Novel salts of rasagiline
CN116916922B (zh) (s,e)-4-(二甲胺基)-n-(3-(4-(2-羟基-1-苯乙胺基)-6-苯基呋喃并[2,3-d]嘧啶-5-基)苯基)丁-2-烯酰胺游离碱的晶型
RU2007123712A (ru) КРИСТАЛЛИЧЕСКИЕ МОДИФИКАЦИИ N-α-(2,4,6-ТРИИЗОПРОПИЛФЕНИЛСУЛЬФОНИЛ)-3-ГИДРОКСИАМИДИНО-(L)-ФЕНИЛАЛАНИН-4-ЭТОКСИКАРБОНИЛПИПЕРАЗИДА И/ИЛИ ЕГО СОЛЕЙ
US9981912B2 (en) Cocrystal of lorcaserin, preparation methods, pharmaceutical compositions and uses thereof
JPWO2010032731A1 (ja) 結晶態様のベンゾイミダゾール化合物又はその塩
JPWO2020247345A5 (https=)
JPWO2023116882A5 (https=)
JP2008195654A (ja) ベンゾ［ｂ］フラン化合物の新規結晶形
JPWO2023011358A5 (https=)